Welcome to what will soon be the most convenient way to stay up-to-date with the key scientific advancements in Cancer Immunotherapy.
ACIR's mission is to fast-track Cancer Immunotherapy Research by helping YOU to stay on top of the new literature in this fast moving and multifaceted field, fostering YOUR creativity and productivity in bringing us ever closer to curing this deadly disease.
Sign up now for our newsletter!
The Fritsch Foundation
515 Providence Highway Suite 103
Dedham, MA 02026
Cancer immunotherapy is a rapidly evolving field that holds much justified hope and promise based on the striking and durable clinical activity observed in multiple patients. Many key elements for constructing highly effective cancer immunotherapies have been identified and new advancements are being made daily. Clinicians and researchers around the world are beginning to understand how to put these pieces together and moving closer to our primary goal of bringing lasting benefit to all victims of this horrible disease.
Accelerating Cancer Immunotherapy Research (ACIR.org) is supported by the Fritsch Foundation, a charitable organization formed following the untimely death of two beloved family members to cancer. The mission of the Fritsch Foundation is to help cure cancer by accelerating the advancement of cancer immunotherapy. ACIR.org was established by the Foundation to carry out this mission by providing, free-of-charge and readily accessible on the internet, a weekly synopsis of the key advances in this fast moving and multifaceted field. Up-to-date knowledge is critical to fostering the necessary creativity and productivity of researchers but this is a daunting, time-consuming and inefficient task for individual researchers, and thus often left undone. We hope that by making it easier for all researchers to stay up to date, our summary will enhance the work of many, bringing us ever closer to curing this deadly disease.
Ed Fritsch, President Ute Burkhardt, Chief Medical Scientist
Our understanding of the interaction between the immune system and cancer cells, and also the ways to exploit this interaction clinically, is growing faster than ever before. At present, there is no reliable single source of information that can help clinicians and researchers in this field stay up-to-date, and by filling this gap, the Fritsch Foundation and ACIR.org initiative will facilitate the development of effective cancer immunotherapies for an increasing number of patient groups.
Ton Schumacher, PhD
Deputy Director of the Netherlands Cancer Institute; Professor of Immunotechnology at Leiden University, The Netherlands; Chief Scientific Officer of Kite Pharma EU; SU2C-CRI Immunotherapy Dream Team member.
The work of ACIR and the Fritsch Foundation is so beautifully targeted on something that has the potential of being truly useful even in the earliest stages. What a great idea!
John Petricciani, MD
President of the International Alliance for Biological Standardization (IABS); Former Director of the Center for Biologics at FDA and former Chief Medical Officer of the Biologicals Unit at WHO.
I fully endorse the mission of the Fritsch Foundation and ACIR.org to provide a weekly synopsis of the scientific literature that bears on the field of cancer immunotherapy. The value and impact of this approach has been clearly demonstrated by a program I have been involved in as a member of the scientific advisory board of the Prize4Life Foundation, which is dedicated to curing the neurodegenerative disease ALS (Amyotrophic Lateral Sclerosis or Lou Gherig’s disease). ALS Forum, a joint effort between Prize4Life and the Alzheimer’s Research Forum provides ALS research summaries and well as links to ALS review articles as well as other content related to clinical trials. This program is widely used by the ALS research community to keep up to date with the rapidly moving scientific literature on ALS.
Tom Maniatis, PhD
Chairman of the Department of Biochemistry and Molecular Biophysics at the Columbia University Medical Center (CUMC) in New York, and Director of the University wide Columbia Precision Medicine Initiative (CPMI) http://newsroom.cumc.columbia.edu/precision-medicine/. A key component of this initiative is cancer genomics and immunotherapy a joint program between CUMC and the New York Presbyterian Hospital.